JP6078536B2 - Ｃ型肝炎ウイルス阻害剤 - Google Patents
Ｃ型肝炎ウイルス阻害剤 Download PDFInfo
- Publication number
- JP6078536B2 JP6078536B2 JP2014515914A JP2014515914A JP6078536B2 JP 6078536 B2 JP6078536 B2 JP 6078536B2 JP 2014515914 A JP2014515914 A JP 2014515914A JP 2014515914 A JP2014515914 A JP 2014515914A JP 6078536 B2 JP6078536 B2 JP 6078536B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- hcv
- halo
- mmol
- interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(CCC[C@](C)[C@](*)C(N(C1)[C@]2C[C@]1Oc(nc1)c(cccc3)c3c1OC)=O)C=C[C@@](C1)[C@]1(C(N[S@@](C1CC1)=CC)=O)NC2=O Chemical compound CC(CCC[C@](C)[C@](*)C(N(C1)[C@]2C[C@]1Oc(nc1)c(cccc3)c3c1OC)=O)C=C[C@@](C1)[C@]1(C(N[S@@](C1CC1)=CC)=O)NC2=O 0.000 description 4
- WMBDDTUBUOEKTM-UHFFFAOYSA-N CC(C)(C)OC(N=C)=O Chemical compound CC(C)(C)OC(N=C)=O WMBDDTUBUOEKTM-UHFFFAOYSA-N 0.000 description 2
- BQVKJNVVQIBILF-UHFFFAOYSA-N COc(cn1)c(cccc2)c2c1[O]=C Chemical compound COc(cn1)c(cccc2)c2c1[O]=C BQVKJNVVQIBILF-UHFFFAOYSA-N 0.000 description 2
- OGYNFRCSDAUNAQ-FTVKEXHGSA-N C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(NS(C1CC1)(=O)=O)=O)NC([C@H](C[C@H](C1)Oc(nc2)c(ccc(OC)c3)c3c2OC)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C(F)(F)F)=O Chemical compound C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(NS(C1CC1)(=O)=O)=O)NC([C@H](C[C@H](C1)Oc(nc2)c(ccc(OC)c3)c3c2OC)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C(F)(F)F)=O OGYNFRCSDAUNAQ-FTVKEXHGSA-N 0.000 description 2
- VCTQGDNFILRGER-UHFFFAOYSA-N CC(C)(C(F)(F)F)OC(N=C)=O Chemical compound CC(C)(C(F)(F)F)OC(N=C)=O VCTQGDNFILRGER-UHFFFAOYSA-N 0.000 description 1
- QXVZMMCQAYIZOI-SHARSMKWSA-N CCOC(C([C@H](C)CCCC(C)C=C)NC(OC(C)(C)C)=O)=O Chemical compound CCOC(C([C@H](C)CCCC(C)C=C)NC(OC(C)(C)C)=O)=O QXVZMMCQAYIZOI-SHARSMKWSA-N 0.000 description 1
- ITVVDKFBWYVGPV-UHFFFAOYSA-N COc(c1c2cccc1)cnc2O Chemical compound COc(c1c2cccc1)cnc2O ITVVDKFBWYVGPV-UHFFFAOYSA-N 0.000 description 1
- BRRYKXRVCAAAHT-UBVCNFCFSA-N C[C@H](CCCC(C)C=C)[C@@H](C(N(C[C@@H](C1)Oc(nc2)c(cccc3)c3c2OC)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(N/S(/C1CC1)=C/C)=O)=O)=O)NC(OC(C)(C)C)=O Chemical compound C[C@H](CCCC(C)C=C)[C@@H](C(N(C[C@@H](C1)Oc(nc2)c(cccc3)c3c2OC)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(N/S(/C1CC1)=C/C)=O)=O)=O)NC(OC(C)(C)C)=O BRRYKXRVCAAAHT-UBVCNFCFSA-N 0.000 description 1
- GYUKXXHNALVLON-WXISSYIKSA-N C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@@]1(C)C(NS(C1(C)CC1)(=O)=O)=O)[C@@H](C(N(C[C@@H](C1)Oc(nc2)c(cccc3Cl)c3c2OC)[C@@H]1C(N)=O)=O)NC(OC(C)(C)C(F)(F)F)=O Chemical compound C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@@]1(C)C(NS(C1(C)CC1)(=O)=O)=O)[C@@H](C(N(C[C@@H](C1)Oc(nc2)c(cccc3Cl)c3c2OC)[C@@H]1C(N)=O)=O)NC(OC(C)(C)C(F)(F)F)=O GYUKXXHNALVLON-WXISSYIKSA-N 0.000 description 1
- XPVROWXOSCLZJL-MAQNSRBKSA-N C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(N/S(/C1CC1)=C/C)=O)NC([C@H](C[C@H](C1)Oc2nc(ccc(OC)c3)c3nc2)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C)=O Chemical compound C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(N/S(/C1CC1)=C/C)=O)NC([C@H](C[C@H](C1)Oc2nc(ccc(OC)c3)c3nc2)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C)=O XPVROWXOSCLZJL-MAQNSRBKSA-N 0.000 description 1
- NUNVFFBWYZOEQJ-LVUCJLHGSA-N C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(N/S(/C1CC1)=C/C)=O)NC([C@H]1N2CCC1)=O)CC2=O Chemical compound C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(N/S(/C1CC1)=C/C)=O)NC([C@H]1N2CCC1)=O)CC2=O NUNVFFBWYZOEQJ-LVUCJLHGSA-N 0.000 description 1
- GMKCUAUZUBXIMA-JMKAVEGQSA-N C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(NS(C1CC1)(=O)=O)=O)NC([C@H](C[C@H](C1)Oc(nc2)c(cc(cc3)F)c3c2OC)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C(F)(F)F)=O Chemical compound C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(NS(C1CC1)(=O)=O)=O)NC([C@H](C[C@H](C1)Oc(nc2)c(cc(cc3)F)c3c2OC)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C(F)(F)F)=O GMKCUAUZUBXIMA-JMKAVEGQSA-N 0.000 description 1
- SFYVIJSLWJFQMF-VMROBCOOSA-N C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(NS(C1CC1)(=O)=O)=O)NC([C@H](C[C@H](C1)Oc(nc2)c(ccc(OC)c3)c3c2OC)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C)=O Chemical compound C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(NS(C1CC1)(=O)=O)=O)NC([C@H](C[C@H](C1)Oc(nc2)c(ccc(OC)c3)c3c2OC)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C)=O SFYVIJSLWJFQMF-VMROBCOOSA-N 0.000 description 1
- YUAYEOCECLXPKP-DYDAHKGKSA-N C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(NS(C1CC1)=O)=O)NC([C@H](C[C@H](C1)Oc(nc2)c(ccc(OC)c3)c3c2OC)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C)=O Chemical compound C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(NS(C1CC1)=O)=O)NC([C@H](C[C@H](C1)Oc(nc2)c(ccc(OC)c3)c3c2OC)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C)=O YUAYEOCECLXPKP-DYDAHKGKSA-N 0.000 description 1
- RIYODWLHOJRUCU-SAPHJPISSA-N C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(NSC1CC1)=O)NC([C@H]1N2CCC1)=O)CC2=O Chemical compound C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(NSC1CC1)=O)NC([C@H]1N2CCC1)=O)CC2=O RIYODWLHOJRUCU-SAPHJPISSA-N 0.000 description 1
- JHYYUHMCQYCWAV-XRWWVIAHSA-N C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(N[SiH2]C1CC1)=O)NC([C@H](C[C@H](C1)Oc2nc(cc(cc3)OC)c3nc2)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C(F)(F)F)=O Chemical compound C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(N[SiH2]C1CC1)=O)NC([C@H](C[C@H](C1)Oc2nc(cc(cc3)OC)c3nc2)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C(F)(F)F)=O JHYYUHMCQYCWAV-XRWWVIAHSA-N 0.000 description 1
- OCNZKERDADTXCZ-DLYUBGHWSA-N C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(CC(NS(C1(C)CC1)(=O)=O)=O)NC([C@H](C[C@H](C1)Oc(nc2)c(ccc(OC)c3)c3c2OC)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C(F)(F)F)=O Chemical compound C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(CC(NS(C1(C)CC1)(=O)=O)=O)NC([C@H](C[C@H](C1)Oc(nc2)c(ccc(OC)c3)c3c2OC)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C(F)(F)F)=O OCNZKERDADTXCZ-DLYUBGHWSA-N 0.000 description 1
- VUEPOCNGLHFECA-JBAHQMPISA-N C[C@H](CCC[C@H](C)/C=C\[C@H](C1)[C@]1(C(NS(C1CC1)=O)=O)NC([C@H](C[C@H](C1)Oc2nc(ccc(OC)c3)c3nc2)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C)=O Chemical compound C[C@H](CCC[C@H](C)/C=C\[C@H](C1)[C@]1(C(NS(C1CC1)=O)=O)NC([C@H](C[C@H](C1)Oc2nc(ccc(OC)c3)c3nc2)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C)=O VUEPOCNGLHFECA-JBAHQMPISA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161497141P | 2011-06-15 | 2011-06-15 | |
| US61/497,141 | 2011-06-15 | ||
| PCT/US2012/042038 WO2012173983A1 (en) | 2011-06-15 | 2012-06-12 | Hepatitis c virus inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014522809A JP2014522809A (ja) | 2014-09-08 |
| JP2014522809A5 JP2014522809A5 (cg-RX-API-DMAC7.html) | 2015-07-09 |
| JP6078536B2 true JP6078536B2 (ja) | 2017-02-08 |
Family
ID=46331708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014515914A Expired - Fee Related JP6078536B2 (ja) | 2011-06-15 | 2012-06-12 | Ｃ型肝炎ウイルス阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8691757B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2721053B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6078536B2 (cg-RX-API-DMAC7.html) |
| AR (1) | AR086934A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013032049A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2839400A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA024173B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2604690T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2013014002A (cg-RX-API-DMAC7.html) |
| TW (1) | TW201305173A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012173983A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009000236A (es) | 2006-07-07 | 2009-01-23 | Gilead Sciences Inc | Compuestos de fosfinato antivirales. |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| DK2909205T3 (en) | 2012-10-19 | 2017-03-06 | Bristol Myers Squibb Co | 9-METHYL-SUBSTITUTED HEXADECAHYDROCYCLOPROPA (E) PYRROL (1,2-A) (1,4) DIAZOCYCLOPENTADECINYLCARBAMATE DERIVATIVES AS NON-STRUCTURAL 3 (NS3) PROTEASE INHIBITORS FOR TREATMENT |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| CN103113324B (zh) * | 2013-02-07 | 2015-08-05 | 浙江工业大学 | 一种n-磺酰基取代的四氢吡咯类化合物的制备方法 |
| EP2964664B1 (en) | 2013-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| ES2735355T3 (es) | 2013-03-15 | 2019-12-18 | Gilead Sciences Inc | Inhibidores macrocíclicos y bicíclicos de virus de hepatitis C |
Family Cites Families (177)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0475255A3 (en) | 1990-09-12 | 1993-04-14 | F. Hoffmann-La Roche Ag | Process for the preparation of optically pure (s)-alpha-((tert-butylsulfonyl)methyl)hydro cinnamic acid |
| EA001915B1 (ru) | 1996-10-18 | 2001-10-22 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы серин-протеаз, в частности ns3 протеазы вируса гепатита c (hvc) |
| DK1003775T3 (da) | 1997-08-11 | 2005-05-30 | Boehringer Ingelheim Ca Ltd | Hepatitis C-inhibitorpeptider |
| AU757072B2 (en) | 1997-08-11 | 2003-01-30 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptide analogues |
| AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| US7012066B2 (en) | 2000-07-21 | 2006-03-14 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| JP3889708B2 (ja) | 2000-11-20 | 2007-03-07 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎トリペプチド阻害剤 |
| US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
| CA2370396A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| US6828301B2 (en) | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| WO2004043339A2 (en) | 2002-05-20 | 2004-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkyl p1' hepatitis c virus inhibitors |
| ES2350201T3 (es) | 2002-05-20 | 2011-01-20 | Bristol-Myers Squibb Company | Sulfamidas heterocíclicas como inhibidores del virus de la hepatitis c. |
| PL215228B1 (pl) | 2002-05-20 | 2013-11-29 | Bristol Myers Squibb Co | Zwiazki tripeptydowe, ich zastosowanie i kompozycja farmaceutyczna je zawierajaca oraz jej zastosowanie |
| US20060199773A1 (en) | 2002-05-20 | 2006-09-07 | Sausker Justin B | Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US20040033959A1 (en) | 2002-07-19 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
| US7601709B2 (en) | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
| EP1590442A4 (en) | 2003-02-07 | 2007-07-18 | Enanta Pharm Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
| CA2516018C (en) | 2003-03-05 | 2011-08-23 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
| WO2004101605A1 (en) | 2003-03-05 | 2004-11-25 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibiting compounds |
| UA81028C2 (en) | 2003-04-02 | 2007-11-26 | Boehringer Ingelheim Int | Pharmaceutical compositions for hepatitis c viral protease inhibitors |
| DE602004019518D1 (de) | 2003-04-16 | 2009-04-02 | Bristol Myers Squibb Co | Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus |
| EP2143727B1 (en) | 2003-04-18 | 2015-01-21 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
| EP1654261B1 (en) | 2003-05-21 | 2007-11-14 | Boehringer Ingelheim International GmbH | Hepatitis c inhibitor compounds |
| WO2004113365A2 (en) | 2003-06-05 | 2004-12-29 | Enanta Pharmaceuticals, Inc. | Hepatitis c serine protease tri-peptide inhibitors |
| US7125845B2 (en) | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
| DE602004031645D1 (de) | 2003-09-22 | 2011-04-14 | Boehringer Ingelheim Pharma | Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus |
| CA2541634A1 (en) | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| RS20060259A (sr) | 2003-10-14 | 2008-08-07 | Intermune Inc., | Makrociklične karboksilne kiseline i acilsulfonamidi kao inhibitori replikacije hcv |
| US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2005051980A1 (en) | 2003-11-20 | 2005-06-09 | Schering Corporation | Depeptidized inhibitors of hepatitis c virus ns3 protease |
| WO2005070955A1 (en) | 2004-01-21 | 2005-08-04 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
| HRP20100048T1 (hr) | 2004-01-30 | 2010-04-30 | Medivir Ab | Inhibitori hcv ns-3 serin proteaze |
| ES2338666T3 (es) | 2004-03-15 | 2010-05-11 | Boehringer Ingelheim International Gmbh | Procedimiento para la preparacion de dipeptidos macrociclicos adecuados para el tratamiento de infecciones viricas de la hepatitis c. |
| CA2560897C (en) | 2004-03-30 | 2012-06-12 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| WO2006016930A2 (en) | 2004-05-14 | 2006-02-16 | Intermune, Inc. | Methods for treating hcv infection |
| EP1753775B1 (en) | 2004-05-25 | 2012-12-26 | Boehringer Ingelheim International GmbH | Process for preparing acyclic hcv protease inhibitors |
| US7705146B2 (en) | 2004-06-28 | 2010-04-27 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor peptide analogs |
| US20080311077A1 (en) | 2004-07-16 | 2008-12-18 | Kleem Chaudhary | Antiviral Compounds |
| UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
| WO2006007708A1 (en) | 2004-07-20 | 2006-01-26 | Boehringer Engelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
| MX2007002371A (es) | 2004-08-27 | 2007-04-23 | Schering Corp | Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. |
| JP2008513454A (ja) | 2004-09-17 | 2008-05-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 大環状ｈｃｖプロテアーゼインヒビターの調製方法 |
| WO2007001406A2 (en) | 2004-10-05 | 2007-01-04 | Chiron Corporation | Aryl-containing macrocyclic compounds |
| BRPI0517463A (pt) | 2004-10-21 | 2008-10-07 | Pfizer | inibidores da protease do vìrus da hepatite c, composições e tratamentos usando os mesmos |
| US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5667745B2 (ja) | 2005-03-08 | 2015-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 大環状化合物を製造する方法 |
| CA2606195C (en) | 2005-05-02 | 2015-03-31 | Merck And Co., Inc. | Hcv ns3 protease inhibitors |
| US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20060287248A1 (en) | 2005-06-02 | 2006-12-21 | Schering Corporation | Asymmetric dosing methods |
| WO2006130554A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
| EP1898941A2 (en) | 2005-06-02 | 2008-03-19 | Schering Corporation | Controlled-release formulation useful for treating disorders associated with hepatitis c virus |
| WO2006130666A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
| US20070004635A1 (en) | 2005-06-02 | 2007-01-04 | Schering Corporation | Method of treating interferon non-responders using HCV protease inhibitor |
| WO2006130687A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor |
| WO2006130552A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
| US20060276405A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods for treating hepatitis C |
| AU2006252519B2 (en) | 2005-06-02 | 2012-08-30 | Merck Sharp & Dohme Corp. | HCV protease inhibitors in combination with food |
| PE20070011A1 (es) | 2005-06-02 | 2007-03-08 | Schering Corp | Formulaciones farmaceuticas de compuestos inhibidores de proteasa del vhc o catepsina |
| US20060281689A1 (en) | 2005-06-02 | 2006-12-14 | Schering Corporation | Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period |
| US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI389908B (zh) | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
| TW200738742A (en) | 2005-07-14 | 2007-10-16 | Gilead Sciences Inc | Antiviral compounds |
| JP2009501732A (ja) | 2005-07-20 | 2009-01-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎インヒビターペプチド類似体 |
| US7470664B2 (en) | 2005-07-20 | 2008-12-30 | Merck & Co., Inc. | HCV NS3 protease inhibitors |
| EP2305697A3 (en) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
| JP5230415B2 (ja) | 2005-07-29 | 2013-07-10 | テイボテク・フアーマシユーチカルズ | Ｃ型肝炎ウイルスの大員環状阻害剤 |
| DK1912996T3 (da) | 2005-07-29 | 2012-09-17 | Janssen R & D Ireland | Makrocykliske inhibitorer af hepatitis C-virus |
| EP1919904B1 (en) | 2005-07-29 | 2014-01-08 | Janssen R&D Ireland | Macrocyclic inhibitors of hepatitis c virus |
| TW200745061A (en) | 2005-07-29 | 2007-12-16 | Tibotec Pharm Ltd | Macrocylic inhibitors of hepatitis C virus |
| RU2419619C2 (ru) | 2005-07-29 | 2011-05-27 | Медивир Аб | Макроциклические ингибиторы вируса гепатита с |
| SI1919898T1 (sl) | 2005-07-29 | 2011-05-31 | Tibotec Pharm Ltd | Makrociklični inhibitorji virusa hepatitisa C |
| ES2449540T3 (es) | 2005-07-29 | 2014-03-20 | Janssen R&D Ireland | Inhibidores macrocíclicos del virus de la hepatitis C |
| JO2768B1 (en) | 2005-07-29 | 2014-03-15 | تيبوتيك فارماسيوتيكالز ليمتد | Large cyclic inhibitors of hepatitis C virus |
| PE20070343A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
| PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| PE20070210A1 (es) | 2005-07-29 | 2007-04-16 | Tibotec Pharm Ltd | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| US8278322B2 (en) | 2005-08-01 | 2012-10-02 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| WO2007016476A2 (en) | 2005-08-01 | 2007-02-08 | Phenomix Corporation | Hepatitis c serine protease inhibitors and uses therefor |
| AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| CA2624333A1 (en) | 2005-10-11 | 2007-04-19 | Intermune, Inc. | Compounds and methods for inhibiting hepatitis c viral replication |
| US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2007082131A1 (en) | 2006-01-09 | 2007-07-19 | Bristol-Myers Squibb Company | Process for the preparation of hydroxy substituted heterocycles |
| CA2644389A1 (en) | 2006-03-03 | 2007-09-20 | Schering Corporation | Pharmaceutical combinations of hcv-protease and -ires inhibitors |
| GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US20070281884A1 (en) | 2006-06-06 | 2007-12-06 | Ying Sun | Macrocyclic oximyl hepatitis C protease inhibitors |
| US8268776B2 (en) | 2006-06-06 | 2012-09-18 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
| GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| AR061629A1 (es) | 2006-06-26 | 2008-09-10 | Enanta Pharm Inc | Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas |
| RU2008152171A (ru) | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| MX2009000236A (es) | 2006-07-07 | 2009-01-23 | Gilead Sciences Inc | Compuestos de fosfinato antivirales. |
| EP2049474B1 (en) | 2006-07-11 | 2015-11-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| DK2041156T3 (en) | 2006-07-13 | 2014-02-24 | Achillion Pharmaceuticals Inc | 4-AMINO-4-OXOBUTANOYL Peptides AS INHIBITORS OF VIRUS REPLICATION |
| CA2656816A1 (en) | 2006-08-04 | 2008-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazolyl macrocyclic hepatitis c serine protease inhibitors |
| WO2008019303A2 (en) | 2006-08-04 | 2008-02-14 | Enanta Pharmaceuticals, Inc. | Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors |
| US20090035267A1 (en) | 2007-07-31 | 2009-02-05 | Moore Joel D | Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors |
| US7635683B2 (en) | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
| WO2008021960A2 (en) | 2006-08-11 | 2008-02-21 | Enanta Pharmaceuticals, Inc. | Triazolyl macrocyclic hepatitis c serine protease inhibitors |
| US7605126B2 (en) | 2006-08-11 | 2009-10-20 | Enanta Pharmaceuticals, Inc. | Acylaminoheteroaryl hepatitis C virus protease inhibitors |
| US20080038225A1 (en) | 2006-08-11 | 2008-02-14 | Ying Sun | Triazolyl acyclic hepatitis c serine protease inhibitors |
| US7582605B2 (en) | 2006-08-11 | 2009-09-01 | Enanta Pharmaceuticals, Inc. | Phosphorus-containing hepatitis C serine protease inhibitors |
| WO2008022006A2 (en) | 2006-08-11 | 2008-02-21 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis c virus protease inhibitors |
| US20090035268A1 (en) | 2007-08-01 | 2009-02-05 | Ying Sun | Tetrazolyl acyclic hepatitis c serine protease inhibitors |
| EP2076278B1 (en) | 2006-10-24 | 2015-05-06 | Merck Sharp & Dohme Corp. | Macrocyclic HCV NS3 protease inhibitors |
| WO2008051475A2 (en) | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| EP2079480B1 (en) | 2006-10-24 | 2013-06-05 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| EP2083844B1 (en) | 2006-10-27 | 2013-11-27 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| BRPI0718161A2 (pt) | 2006-10-27 | 2013-11-26 | Merck & Co Inc | Composto, composição farmacêutica, e, uso do composto. |
| US20080107625A1 (en) | 2006-11-01 | 2008-05-08 | Bristol-Myers Squibb Company | Inhibitors of Hepatitis C Virus |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US20080107623A1 (en) | 2006-11-01 | 2008-05-08 | Bristol-Myers Squibb Company | Inhibitors of Hepatitis C Virus |
| US20080108632A1 (en) | 2006-11-02 | 2008-05-08 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008070358A2 (en) | 2006-11-16 | 2008-06-12 | Phenomix Corporation | N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain |
| US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI406660B (zh) | 2006-11-17 | 2013-09-01 | Tibotec Pharm Ltd | Ｃ型肝炎病毒之巨環抑制劑 |
| US20080207528A1 (en) | 2007-02-01 | 2008-08-28 | Syaulan Yang | Hcv protease inhibitors |
| AR065136A1 (es) | 2007-02-01 | 2009-05-20 | Tibotec Pharm Ltd | Formas polimorficas de un inhibidor macrociclico de vhc. procesos de obtencion y composiciones farmaceuticas. |
| AU2008209697B2 (en) | 2007-02-01 | 2014-02-20 | Janssen Sciences Ireland Uc | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV |
| MX2009008541A (es) | 2007-02-08 | 2009-08-18 | Tibotec Pharm Ltd | Fenilcarbamatos macrociclicos que inhiben el virus de hepatitis c. |
| WO2008096002A1 (en) | 2007-02-08 | 2008-08-14 | Tibotec Pharmaceuticals Ltd. | Hcv inhibiting macrocyclic phosphonates and amidophosphates |
| ES2541660T3 (es) | 2007-02-08 | 2015-07-23 | Janssen Sciences Ireland Uc | Inhibidores del VHC macrocíclicos sustituidos con pirimidina |
| US20100087382A1 (en) | 2007-02-16 | 2010-04-08 | Boehringer Ingelheim International Gmbh | Inhibitors of Hepatitis C NS3 Protease |
| MX2009008872A (es) | 2007-02-20 | 2009-10-30 | Novartis Ag | Compuestos macrociclicos como inhibidores de proteasa ns3 del virus de hepatitis c. |
| WO2008106130A2 (en) | 2007-02-26 | 2008-09-04 | Achillion Pharmaceuticals, Inc. | Tertiary amine substituted peptides useful as inhibitors of hcv replication |
| BRPI0810665A2 (pt) | 2007-04-24 | 2014-11-04 | Hoffmann La Roche | Processo para a preparação de intermediário de inibidor da protease de hcv |
| US20080274080A1 (en) | 2007-04-26 | 2008-11-06 | Yat Sun Or | Aza-peptide macrocyclic hepatitis c serine protease inhibitors |
| US20080292587A1 (en) | 2007-04-26 | 2008-11-27 | Ying Sun | Oximyl dipeptide hepatitis c protease inhibitors |
| WO2008134397A1 (en) | 2007-04-26 | 2008-11-06 | Enanta Pharmaceuticals, Inc. | Aza-tripeptide hepatitis c serine protease inhibitors |
| US20080279821A1 (en) | 2007-04-26 | 2008-11-13 | Deqiang Niu | Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors |
| JP2010528987A (ja) | 2007-05-03 | 2010-08-26 | インターミューン・インコーポレーテッド | Ｃ型肝炎ウイルス複製の新規大環状阻害剤 |
| US7932277B2 (en) | 2007-05-10 | 2011-04-26 | Intermune, Inc. | Peptide inhibitors of hepatitis C virus replication |
| BRPI0813733A2 (pt) | 2007-06-29 | 2019-11-05 | Gilead Sciences Inc | composto com atividade inibidora de hcv, sua composição farmacêutica e seu uso. |
| US20090047252A1 (en) | 2007-06-29 | 2009-02-19 | Gilead Sciences, Inc. | Antiviral compounds |
| US8927569B2 (en) | 2007-07-19 | 2015-01-06 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as antiviral agents |
| WO2009014730A1 (en) | 2007-07-26 | 2009-01-29 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| WO2009070692A1 (en) | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| TW201546079A (zh) | 2007-12-21 | 2015-12-16 | Celgene Avilomics Res Inc | Ｈｃｖ蛋白酶抑制劑及其用途（一） |
| US8048862B2 (en) | 2008-04-15 | 2011-11-01 | Intermune, Inc. | Macrocyclic inhibitors of hepatitis C virus replication |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20090285774A1 (en) | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20090285773A1 (en) | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8044023B2 (en) | 2008-05-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201023858A (en) | 2008-09-18 | 2010-07-01 | Ortho Mcneil Janssen Pharm | Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside |
| WO2010031832A2 (en) | 2008-09-18 | 2010-03-25 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20100080770A1 (en) | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20100272674A1 (en) | 2008-12-04 | 2010-10-28 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| EA023433B1 (ru) | 2009-07-07 | 2016-06-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Фармацевтическая композиция ингибитора протеазы вируса гепатита c |
| US20110129444A1 (en) | 2009-09-28 | 2011-06-02 | Intermune, Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
| KR20130026410A (en) | 2009-09-28 | 2013-03-13 | Intermune Inc | Cyclic peptide inhibitors of hepatitis c virus replication |
| US8415374B2 (en) | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
| JP2013511562A (ja) | 2009-11-24 | 2013-04-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎阻害化合物 |
| NZ599963A (en) | 2009-12-18 | 2014-02-28 | Boehringer Ingelheim Int | Hcv combination therapy |
| US20120196794A1 (en) | 2010-08-06 | 2012-08-02 | Bristol-Myers Squibb Company | Combinations of Hepatitis C Virus Inhibitors |
| US20120095211A1 (en) | 2010-09-22 | 2012-04-19 | Intermune, Inc. | Substituted proline inhibitors of hepatitis c virus replication |
| US8951964B2 (en) | 2010-12-30 | 2015-02-10 | Abbvie Inc. | Phenanthridine macrocyclic hepatitis C serine protease inhibitors |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN103562199B (zh) | 2011-05-27 | 2016-03-30 | 百时美施贵宝公司 | 作为丙型肝炎病毒抑制剂的掺入氘的三肽 |
-
2012
- 2012-06-11 US US13/492,982 patent/US8691757B2/en active Active
- 2012-06-12 WO PCT/US2012/042038 patent/WO2012173983A1/en not_active Ceased
- 2012-06-12 JP JP2014515914A patent/JP6078536B2/ja not_active Expired - Fee Related
- 2012-06-12 ES ES12729291.0T patent/ES2604690T3/es active Active
- 2012-06-12 MX MX2013014002A patent/MX2013014002A/es unknown
- 2012-06-12 CA CA2839400A patent/CA2839400A1/en not_active Abandoned
- 2012-06-12 EP EP12729291.0A patent/EP2721053B1/en not_active Not-in-force
- 2012-06-12 EA EA201391717A patent/EA024173B1/ru not_active IP Right Cessation
- 2012-06-12 BR BR112013032049A patent/BR112013032049A2/pt not_active IP Right Cessation
- 2012-06-14 AR ARP120102114A patent/AR086934A1/es unknown
- 2012-06-14 TW TW101121400A patent/TW201305173A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201305173A (zh) | 2013-02-01 |
| US8691757B2 (en) | 2014-04-08 |
| JP2014522809A (ja) | 2014-09-08 |
| CA2839400A1 (en) | 2012-12-20 |
| EA201391717A1 (ru) | 2014-04-30 |
| CN103732613A (zh) | 2014-04-16 |
| WO2012173983A1 (en) | 2012-12-20 |
| EP2721053B1 (en) | 2016-10-19 |
| ES2604690T3 (es) | 2017-03-08 |
| EA024173B1 (ru) | 2016-08-31 |
| AR086934A1 (es) | 2014-01-29 |
| BR112013032049A2 (pt) | 2016-09-13 |
| US20130142754A1 (en) | 2013-06-06 |
| EP2721053A1 (en) | 2014-04-23 |
| MX2013014002A (es) | 2014-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6078536B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| CN102317306B (zh) | 丙型肝炎病毒抑制剂 | |
| JP5487209B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5450604B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5474940B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5221552B2 (ja) | Ｃ型肝炎ウイルス阻害剤としての大環状ペプチド | |
| JP5241728B2 (ja) | Ｃ型肝炎ウイルス阻害剤としての大環状ペプチド | |
| TWI542589B (zh) | Ｃ型肝炎病毒抑制劑 | |
| CN102307890B (zh) | 丙型肝炎病毒抑制剂 | |
| JP5529120B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP2012504126A (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP6110846B2 (ja) | Ｃ型肝炎ウイルス阻害剤としての重水素が導入されたトリペプチド | |
| JP2012504129A (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP2011521911A (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| TW200946523A (en) | Hepatitis C virus inhibitors | |
| TW201422620A (zh) | Ｃ型肝炎病毒抑制劑 | |
| JP6342922B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| CN103732613B (zh) | 丙型肝炎病毒抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150518 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150518 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160219 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160607 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160826 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170110 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170116 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6078536 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |